Kronos Bio Inc.
disclosed Thursday that its initial public offering was upsized by about 28%, as the California-based biopharmaceutical now looks to raise up to $236.8 million.
The company is now offering 13,147,895 shares in the IPO, up from 10,294,118, while the pricing is still expected to be between $16 and $18 a share.
With 54.2 million shares now expected to be outstanding after the IPO, up from 51.3 million, the company could be valued at up to $975.5 million. The shares are expected to list on the Nasdaq under the ticker symbol “KRON.”